.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The INBUILD trial evaluated nintedanib in patients with progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis. The randomized placebo-controlled study showed that nintedanib slowed the rate of decline in forced vital capacity across a broad group of fibrosing ILDs with a progressive phenotype. The benefit was consistent across major diagnostic subgroups, supporting the concept that treatment decisions can sometimes be guided by disease behavior rather than diagnosis alone. The clinical relevance is substantial for pulmonary practice because patients with connective-tissue-disease-associated ILD, chronic hypersensitivity pneumonitis, and other fibrosing disorders may develop a progressive trajectory even when they do not meet criteria for IPF. For HCPs, the paper supports regular assessment of change over time and timely referral to an ILD-focused multidisciplinary service when progression is suspected. As with IPF, adverse effects—especially diarrhea—need active management. The findings directly support the conference’s emphasis on antifibrotics beyond classic IPF and on longitudinal imaging, pulmonary function, and trajectory rather than relying on a single scan or isolated measurement.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The INBUILD trial evaluated nintedanib in patients with progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis. The randomized placebo-controlled study showed that nintedanib slowed the rate of decline in forced vital capacity across a broad group of fibrosing ILDs with a progressive phenotype. The benefit was consistent across major diagnostic subgroups, supporting the concept that treatment decisions can sometimes be guided by disease behavior rather than diagnosis alone. The clinical relevance is substantial for pulmonary practice because patients with connective-tissue-disease-associated ILD, chronic hypersensitivity pneumonitis, and other fibrosing disorders may develop a progressive trajectory even when they do not meet criteria for IPF. For HCPs, the paper supports regular assessment of change over time and timely referral to an ILD-focused multidisciplinary service when progression is suspected. As with IPF, adverse effects—especially diarrhea—need active management. The findings directly support the conference’s emphasis on antifibrotics beyond classic IPF and on longitudinal imaging, pulmonary function, and trajectory rather than relying on a single scan or isolated measurement.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
